DDInter224 DDInter1376
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Bosutinib {u} (Compound) resembles {v} (Compound) Gefitinib
Bosutinib {u} (Compound) binds {v} (Gene) PTK2
Bosutinib {u} (Compound) upregulates {v} (Gene) HSD17B7
Bosutinib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Bosutinib {u} (Compound) downregulates {v} (Gene) COTL1
Bosutinib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Bosutinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Famotidine
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium carbonate
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Bosutinib (Compound) resembles Gefitinib (Compound)
Bosutinib (Compound) binds PTK2 (Gene)
Bosutinib (Compound) upregulates HSD17B7 (Gene)
Bosutinib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Bosutinib (Compound) downregulates COTL1 (Gene)
Bosutinib (Compound) causes Cardiac disorder (Side Effect)
Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Bosutinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen